[
  {
    "ts": null,
    "headline": "Medtronic Affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients",
    "summary": "Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Affera™ family of technologies, including the next-generation Sphere-360™ single-shot pulsed field ablation (PFA) catheter and the groundbreaking Sphere-9™ combination mapping and dual-energy focal PFA catheter. Data were presented in High Impact Science Sessions at the Heart Rhythm Society 2025 Annual Meeting in",
    "url": "https://finnhub.io/api/news?id=28ac88c3aa21539e492edee3afcf4206ef80278dc3457a0c05876eb62433779b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745709600,
      "headline": "Medtronic Affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients",
      "id": 134104656,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Affera™ family of technologies, including the next-generation Sphere-360™ single-shot pulsed field ablation (PFA) catheter and the groundbreaking Sphere-9™ combination mapping and dual-energy focal PFA catheter. Data were presented in High Impact Science Sessions at the Heart Rhythm Society 2025 Annual Meeting in",
      "url": "https://finnhub.io/api/news?id=28ac88c3aa21539e492edee3afcf4206ef80278dc3457a0c05876eb62433779b"
    }
  },
  {
    "ts": null,
    "headline": "2 Outstanding Dividend Stocks to Buy and Hold For 20 Years",
    "summary": "Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold on through market volatility.  With that, let's consider two dividend-paying companies that look like strong buys for the next two decades: Medtronic (NYSE: MDT) and Merck (NYSE: MRK).  Medtronic, a leader in medical devices, could feel the impact of President Trump's tariffs.",
    "url": "https://finnhub.io/api/news?id=d2f7f4a0216ba2cebeb4bbb0f4c863566ef7d358da174c93e59b58bfb94c0e39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745692320,
      "headline": "2 Outstanding Dividend Stocks to Buy and Hold For 20 Years",
      "id": 134104657,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold on through market volatility.  With that, let's consider two dividend-paying companies that look like strong buys for the next two decades: Medtronic (NYSE: MDT) and Merck (NYSE: MRK).  Medtronic, a leader in medical devices, could feel the impact of President Trump's tariffs.",
      "url": "https://finnhub.io/api/news?id=d2f7f4a0216ba2cebeb4bbb0f4c863566ef7d358da174c93e59b58bfb94c0e39"
    }
  },
  {
    "ts": null,
    "headline": "Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system",
    "summary": "Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced that the Expand URO Investigational Device Exemption (IDE) clinical study, the largest such study for robotic-assisted urologic surgery ever conducted, met both primary safety and effectiveness endpoints. The prospective, multi-center, single-arm IDE study included 137 patients who underwent urologic procedures using the Hugo™ robotic-assisted surgery (RAS) system.",
    "url": "https://finnhub.io/api/news?id=dae66de3c08271ca70588d599173385479c3a2f423ab45c21a7530cbe232a403",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745691600,
      "headline": "Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system",
      "id": 134104658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced that the Expand URO Investigational Device Exemption (IDE) clinical study, the largest such study for robotic-assisted urologic surgery ever conducted, met both primary safety and effectiveness endpoints. The prospective, multi-center, single-arm IDE study included 137 patients who underwent urologic procedures using the Hugo™ robotic-assisted surgery (RAS) system.",
      "url": "https://finnhub.io/api/news?id=dae66de3c08271ca70588d599173385479c3a2f423ab45c21a7530cbe232a403"
    }
  },
  {
    "ts": null,
    "headline": "Medtronic (NYSE:MDT) Secures FDA Approval For Innovative OmniaSecure Defibrillation Lead",
    "summary": "Medtronic (NYSE:MDT) recently announced FDA approval of its OmniaSecure™ defibrillation lead, marking a key advancement in cardiovascular technology, along with results from its LEADR LBBAP study showing a 100% defibrillation success rate. Over the past week, Medtronic's stock price increased by 1.9%, a move that aligned with these positive developments but was modest compared to the broader market's 4.7% rise. While Medtronic's innovative product developments could have added weight to its...",
    "url": "https://finnhub.io/api/news?id=92a59381ee8f5a9828c5d2ae7a8071cba2a60e93b1c6f115d7d933117763e606",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745687840,
      "headline": "Medtronic (NYSE:MDT) Secures FDA Approval For Innovative OmniaSecure Defibrillation Lead",
      "id": 134104659,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Medtronic (NYSE:MDT) recently announced FDA approval of its OmniaSecure™ defibrillation lead, marking a key advancement in cardiovascular technology, along with results from its LEADR LBBAP study showing a 100% defibrillation success rate. Over the past week, Medtronic's stock price increased by 1.9%, a move that aligned with these positive developments but was modest compared to the broader market's 4.7% rise. While Medtronic's innovative product developments could have added weight to its...",
      "url": "https://finnhub.io/api/news?id=92a59381ee8f5a9828c5d2ae7a8071cba2a60e93b1c6f115d7d933117763e606"
    }
  }
]